Magazine Article | March 1, 2019

The Unique Demands of Cell and Gene Therapy Supply Chains

Source: Life Science Leader

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

Innovations in the cell and gene sector continue to advance development of safe and effective therapies. But can the cell and gene therapy sector’s exceptionally complex supply chains keep up with the rapid rate of progress? I conferred with three of the field’s most valuable luminaries representing both academia and industry — Dr. Bruce Levine, Barbara and Edward Netter professor in Cancer Gene Therapy at the University of Pennsylvania; Simon Ellison, ISCT (International Society of Cell & Gene Therapy) Commercialization Committee; and Ryan Bartock, head of supply chain and network strategy at Spark Therapeutics — to determine how CMOs can and should successfully manage cell and gene therapy supply chains.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader